Transaction summaryMetric Value Shares sold (direct) 24,100 Transaction value ~$732,000 Post-transaction shares (direct) 30,547 Post-transaction value (direct ownership) ~$929,000Transaction value based on SEC Form 4 weighted average purchase price ($30.38); post-transaction value based on June 25, 2026 market close ($30.40). Krasney's direct common share holdings decreased by 44.10% to 30,547 shares. No, all shares exercised and sold were held directly by Krasney, with no participation from family trusts, LLCs, or other indirect entities. Operates as a clinical-stage biotechnology company focused on developing therapeutics for rare diseases including Duchenne muscular dystrophy. Capricor Therapeutics is a clinical-stage biotechnology company specializing in innovative therapies for rare and life-threatening diseases.